OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Llovet on Precision Medicine in HCC

October 19th 2018

Josep M. Llovet, MD, PhD, founder and director of the Liver Cancer Program, full professor of medicine, Icahn School of Medicine, Mount Sinai Hospital, discusses the potential for precision medicine in hepatocellular carcinoma.

Dr. Tasian on Frontline Therapy for Pediatric Patients With Ph-Like ALL

October 18th 2018

Sarah K. Tasian, MD, an attending physician and assistant professor of pediatrics in the Division of Oncology at Children’s Hospital of Philadelphia (CHOP), discusses frontline therapy for pediatric patients with Ph-like acute lymphoblastic leukemia (ALL).

Dr. Halmos on Immunotherapy in Squamous NSCLC

October 18th 2018

Balazs Halmos, MD, MS, director of thoracic oncology and director of clinical cancer genomics, Montefiore Medical Center, discusses the use of immunotherapy in the treatment of patients with metastatic squamous non–small cell lung cancer (NSCLC).

Dr. Villaruz on EGFR-Targeted Therapies in NSCLC

October 18th 2018

Liza C. Villaruz, MD, assistant professor of medicine, Division of Hematology/Oncology, University of Pittsburgh, discusses EGFR-targeted therapies in non–small cell lung cancer.

Dr. Gradishar on Personalized Treatment in Breast Cancer

October 17th 2018

William J. Gradishar, MD, chief of hematology and oncology, Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of medicine (hematology and oncology), Northwestern University's Feinberg School of Medicine, discusses the rise of personalized treatment in breast cancer.

Dr. Damon on Drug Development in AML

October 17th 2018

Lloyd Damon, MD, director of the Adult Blood and Marrow Transplant and Hematologic Malignancies Program, and chief of the University of California, San Francisco (UCSF) Hematology Clinic, UCSF Helen Diller Family Comprehensive Cancer Center, discusses drug development in acute myeloid leukemia (AML).

Cosmo Smith on The Breakthrough Oncology Accelerator Flagship Program

October 17th 2018

P. Cosmo Smith, MBA, managing partner, Origin Commercial Ventures, discusses The Breakthrough Oncology Accelerator flagship program.

Dr. Leighl Discusses Binimetinib in KRAS-Mutated NSCLC

October 17th 2018

Natasha Leighl, MD, medical oncologist, Cancer Clinical Research Unit, Princess Margaret Cancer Centre, discusses binimetinib (Mektovi) in KRAS-mutated non–small cell lung cancer.

Next Steps With the St. Jude Lifetime Cohort Study

October 17th 2018

Zhaoming Wang, PhD, bioinformatics scientist, Department of Computational Biology, St. Jude Children’s Research Hospital, discusses the next steps of the St. Jude Lifetime Cohort Study.

Dr. King on Surgical Approaches in Breast Cancer

October 17th 2018

Tari King, MD, FACS, chief of Breast Surgery, Dana-Farber Cancer Institute, Brigham Women’s Cancer Center, discusses surgical approaches in breast cancer.

Dr. Shah on Challenges of CAR T-Cell Clinical Trials in MCL

October 17th 2018

Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, assistant professor of oncology, University of South Florida, discusses the challenges of developing clinical trials for CAR T cells in mantle cell lymphoma.

Dr. Whitman on Eliminating Financial Toxicity in Oncology

October 17th 2018

Eric Whitman, MD, medical director of Atlantic Health System Cancer Care, Atlantic Health System, discusses eliminating financial toxicity in oncology.

Dr. O'Regan on the Status of Biosimilars in Oncology

October 17th 2018

Ruth O’Regan, MD, division head, Hematology and Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, discusses the status of biosimilars in oncology.

Dr. Yardley on the FDA Approval of Talazoparib in Breast Cancer

October 16th 2018

Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses the FDA approval of talazoparib (Talzenna) for the treatment of patients with germline BRCA mutation–positive, HER2-negative locally advanced or metastatic breast cancer

Dr. Kerr on Misconceptions With Molecular Profiling in Lung Cancer

October 16th 2018

Keith Kerr, BSc, MB, ChB, consultant pathologist, University of Aberdeen, Aberdeen, Scotland, discusses common misconceptions with molecular profiling in lung cancer.

Dr. Wang Discusses the Treatment of Relapsed/Refractory MCL

October 16th 2018

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the treatment of patients with relapsed/refractory mantle cell lymphoma.

Dr. Meeks Discusses Smoking Status in Bladder Cancer

October 16th 2018

Joshua Meeks, MD, PhD, assistant professor of urology, biochemistry, and molecular genetics, Northwestern University Feinberg School of Medicine, section chief of robotic surgery, Jesse Brown VA Medical Center, discusses the role of smoking status in the diagnosis of bladder cancer.

Dr. Horn Discusses Next Steps With Atezolizumab in SCLC

October 16th 2018

Leora Horn, MD, associate professor of medicine (hematology and oncology), assistant director, educator development program, clinical director, Thoracic Oncology, medical oncologist, Vanderbilt-Ingram Medical Center, discusses next steps with atezolizumab (Tecentriq) in small cell lung cancer.

Dr. Andreadis on Response to CAR T-Cell Therapy

October 16th 2018

Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses response to chimeric antigen receptor (CAR) T-cell therapy.

Dr. Fakhri on the Use of Carfilzomib in Multiple Myeloma

October 16th 2018

Bita Fakhri, MD, MPH, a professor of medicine in the Division of Hematology/Oncology at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the use of carfilzomib (Kyprolis) in the treatment of patients with multiple myeloma.